Mesoblast Limited announced the appointment of Dr. Eric Rose as the Company's Chief Medical Officer (CMO). Dr. Rose has been a non-executive director of Mesoblast since 2013. In his new role as a key executive, Dr. Rose brings to Mesoblast an extensive record of excellence in clinical development and successful interactions at the highest levels with key regulatory, industry and government stakeholders including the United States Food and Drug Administration (FDA), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 AUD | -1.41% | -7.08% | +238.71% |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
Mar. 28 | ADRs End Lower; NuCana Slides 15% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+238.71% | 805M | |
+26.21% | 49.18B | |
+0.76% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+12.93% | 26.09B | |
-21.87% | 18.71B | |
+9.08% | 13.26B | |
+31.00% | 12.32B | |
-0.61% | 11.99B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Mesoblast Limited Appoints Eric Rose as Chief Medical Officer